HLA-I epitopes were required to have a NetMHCpan (version 3.0) percent rank lower than 2%, and the latter two epitope classes were required to have expression levels > 10 TPM and > 5 TPM, respectively (if none were available, the slots were ceded to HLA-I selections). Generally, each ...
PD-1/PD-L1 antibodies are divided into three classes according to different targets (including PD-1, PD-L1 and PD-L2). In particular, the PD-1 antibodies nivolumab [39] and pembrolizumab [40] were approved by the FDA for treatment of non-small cell lung cancer (NSCLC) in 2015 [17,...
protected classes relative to other drugs. Similarly, Medicaid cost-containment policies that lower Medicaid drug prices relative to Medicare drug prices can bias new R&D in favor of drugs that primarily benefit the elderly. More broadly, in highlighting the interplay between patent law and Medicare ...